Evidence map›Paper›PMID 40191213›Full record

ArticleFrontiers in immunology2025

Enhanced and long-lasting SARS-CoV-2 immune memory in individuals with common cold coronavirus cross-reactive T cell immunity.

David M Florian, Michael Bauer, Amelie Popovitsch, Ingrid Fae, David N Springer, Marianne Graninger, Marianna Traugott, Lukas Weseslindtner, Stephan W Aberle, Gottfried Fischer and 5 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

David M FlorianCenter for Virology, Medical University of Vienna, Vienna, Austria.
Michael BauerCenter for Virology, Medical University of Vienna, Vienna, Austria.
Amelie PopovitschCenter for Virology, Medical University of Vienna, Vienna, Austria.
Ingrid FaeDepartment of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.
David N SpringerCenter for Virology, Medical University of Vienna, Vienna, Austria.
Marianne GraningerCenter for Virology, Medical University of Vienna, Vienna, Austria.
Marianna TraugottDepartment of Medicine IV, Klinik Favoriten, Vienna, Austria.
Lukas WeseslindtnerCenter for Virology, Medical University of Vienna, Vienna, Austria.
Stephan W AberleCenter for Virology, Medical University of Vienna, Vienna, Austria.
Gottfried FischerDepartment of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.
Michael KundiCenter for Public Health, Department for Environmental Health, Medical University of Vienna, Vienna, Austria.
Karin StiasnyCenter for Virology, Medical University of Vienna, Vienna, Austria.
Alexander ZoufalyDepartment of Medicine IV, Klinik Favoriten, Vienna, Austria.
Samuel J LandryDepartment of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Judith H AberleCenter for Virology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the continuous emergence of novel SARS-CoV-2 variants, long-lasting and broadly reactive cellular and humoral immunity is critical for durable protection from COVID-19. We investigated SARS-CoV-2-specific T cell immunity in relation to antibodies, infection outcome and disease severity and assessed its durability in a longitudinal cohort over a three-year time course. We identified pre-existing T cells reactive to the seasonal coronavirus (CoV) OC43 that cross-react with the conserved SARS-CoV-2 spike S

Indexed as

Common ColdCOVID-19Immunologic MemorySARS-CoV-2T-LymphocytesAdultAgedAntibodies, ViralCoronavirus OC43, HumanCross ReactionsFemaleHumansLongitudinal StudiesMaleMiddle AgedSpike Glycoprotein, CoronavirusAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD4 T cell responsecell-mediated immunitylong term immunitymRNA vaccinationSARS-CoV-2

Identifiers

PMID40191213
PMCPMC11968687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.